http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022002015-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5b5a87729886b07681f4081a5626415 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2021-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7c7af8bbca04ae0d303ce2c76e3c70c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7c82bce66df11457f20adcb646a896b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33d6231410259abc112952b1e398dcee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a67c233f3ba4798ab73c7b1b7ef56bc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c40c49d165d1e06765fe66634c8ed6 |
| publicationDate | 2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022002015-A1 |
| titleOfInvention | Polypeptide, hla-dr protein and preparation method therefor and use thereof |
| abstract | Provided in the present invention are a polypeptide, HLA-DR protein and a preparation method therefor and use thereof. The polypeptide is a polypeptide of 8-48 amino acid residues formed by interconnecting glycine and serine by means of peptide bonds; the structural composition of the HLA-DR protein comprises an α chain, a β chain and a polypeptide; the C-terminal of the α chain is connected to the N-terminal of the polypeptide; and the C-terminal of the polypeptide is connected to the N-terminal of the β chain. The protein is obtained by connecting the α chain and the β chain which form the HLA-DR protein by means of specific polypeptides of 8-48 amino acid residues comprising glycine and serine which are interconnected by means of peptide bonds. The designed HLA-DR protein can be expressed in series in mammalian cells, can simulate the expression of sHLA-DR, has a structure similar to that of natural sHLA-DR, has more stable conformation compared with membrane protein mHLA-DR, can adopt an eukaryotic expression system for soluble high efficiency expression, and is expected to have a good application in the field of medical biology and the development of biomedicine. |
| priorityDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.